SCHEMBL1063187

SCHEMBL1063187

COC(=O)c1ccc(CSc2nc3cc(OC)ccc3[nH]2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 11/20 0.68
CYP2C8 P10632 11/20 0.68
CYP2D6 P10635 11/20 0.68
CYP2C9 P11712 11/20 0.68
CYP2B6 P20813 11/20 0.68
CYP2C19 P33261 11/20 0.68
CYP3A4 P08684 10/20 0.68
CYP1A2 P05177 9/20 0.68
MAPT P10636 3/20 0.59
FPR1 P21462 1/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
LMNA P02545 2/20 0.59
RECQL P46063 1/20 0.59
MEN1 O00255 1/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
KMT2A Q03164 1/20 0.59
RELA Q04206 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1064755 0.91 CYP2E1 (0.82) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
Bromide SCHEMBL1064752 0.90 CYP2E1 (0.80) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL1065421 0.90 CYP2E1 (0.83) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL15693611 0.87 RAB9A (0.76) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL1061025 0.84 RAB9A (0.77) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL20379521 0.83 MAPT (0.85) CYP2C9CYP2C19CYP3A4CYP1A2MAPT
SCHEMBL8635405 0.83 MAPT (0.58) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL12195173 0.82 CYP2E1 (0.82) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL211177 0.82 HDAC1 (0.71) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL4650009 0.82 CYP2E1 (0.81) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868204-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7868204-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7868204-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7838520-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2010-11-23 US disclosed
US-7838520-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2010-11-23 US disclosed
US-7838520-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2010-11-23 US disclosed
US-7595343-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2009-09-29 US disclosed
US-7595343-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2009-09-29 US disclosed
US-7595343-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2009-09-29 US disclosed
US-20060058298-A1 Inhibitors of histone deacetylase METHYLGENE, INC. 2006-03-16 US disclosed
US-6897220-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2005-05-24 US disclosed
WO-2004069823-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2004-08-19 WO disclosed
WO-2004069823-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2004-08-19 WO disclosed
US-20040142953-A1 Inhibitors of histone deacetylase METHYLGENE, INC. 2004-07-22 US disclosed
EP-1429765-A2 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2004-06-23 EP disclosed
US-20040106599-A1 Inhibitors of histone deacetylase 92229129 QUEBEC INC. (CA) 2004-06-03 US disclosed
WO-2004005513-A2 METHODS FOR SPECIFICALLY INHIBITING HISTONE DEACETYLASE-7 AND 8 METHYLGENE, INC. (CA) 2004-01-15 WO disclosed
WO-2004005513-A2 METHODS FOR SPECIFICALLY INHIBITING HISTONE DEACETYLASE-7 AND 8 METHYLGENE, INC. (CA) 2004-01-15 WO disclosed
WO-2003024448-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2003-03-27 WO disclosed
WO-2003024448-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106599-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 CYP2E1 4369/4885CYP2C8 4554/4885CYP2D6 4762/4885
US-20060058298-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 CYP2E1 4369/4885CYP2C8 4554/4885CYP2D6 4762/4885
US-20040142953-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 CYP2E1 4369/4885CYP2C8 4554/4885CYP2D6 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.